Ultragenyx Pharmaceutical Inc.
NEWS
Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.
Crysvita is a drug developed by Ultragenyx Pharmaceutical and Tokyo-based Kyowa Kirin Co. Ltd., a specialty pharmaceutical company.
Ultragenyx Pharmaceutical Inc. today announced that Shalini Sharp, the company’s Chief Financial Officer, will present at the Piper Jaffray 31ST Annual Healthcare Conference on Wednesday, December 4, 2019 at 2:00 PM ET in New York, NY.
The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue.
Ultragenyx Pharmaceutical Inc. announced that Emil Kakkis, the company’s Chief Executive Officer and President will present at the Jefferies Gene Therapy/Editing Summit on Tuesday, October 8, 2019 at 9:45 AM ET in New York, NY.
Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. announced plans to submit a supplemental Biologics License Application to the U.S. Food and Drug Administration for Crysvita® for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.
Ultragenyx Pharmaceutical Inc. announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus based gene therapy for the treatment of glycogen storage disease type Ia.
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation and Rare Pediatric Disease Designation to GTX-102 for the treatment of Angelman Syndrome, a serious, debilitating rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide.
Ultragenyx Pharmaceutical Inc. announced that Shalini Sharp, the company’s Chief Financial Officer, will present at the following conferences
JOBS
IN THE PRESS